Inspiralis Limited is a leading Biotech company specialising in DNA modifying enzymes and their substrates. Based on the Norwich Research Park in the UK, for over 15 years they have supported preclinical development of anti-infective and anti-cancer compounds. Either through the supply of their high-quality products or through provision of contract research services in the form of drug screening and mode of action studies.
The meaningful collaborations established with academic groups and the wealth of experience and knowledge of their staff allows them to provide the highest level of support and guidance to researchers, ensuring that optimal results are achieved using Inspiralis’s products and services.
We are located along with a number of other biotech companies in the Norwich Research Park (NRP) Innovation Centre.
The NRP is a world class research centre in plant, food, microbial, health and environmental sciences. The NRP comprises the University of East Anglia, the John Innes Centre, the Quadram Institute, the Earhlam Institute, PBL, and the Norfolk and Norwich University Hospital and UEA Medical School. Over 1500 scientists work in the NRP institutes, along with over 500 post-graduate science students, providing us with opportunities for scientific consultation and collaboration.
Our directors and scientific staff have impressive publication records and bring to the company many years of experience working within the topoisomerase field. They can provide high quality products produced by experienced scientists combined with highly personalised technical support from research labs working closely with the company.
Director and Founder
Nick Burton is a Managing Director of Inspiralis. He is a biochemist who has over 20 years experience in topoisomerase research. As one of the founders of Inspiralis he has been involved in the development of the company from its beginning to its present position. He has experience in the commercialisation of topoisomerase products as well as the development of new products.
Non-Executive Director and Founder
Alison Howells is one of the founding directors having been involved from its original inception to the formation of the current company. She was co. Managing Director of Inspiralis from 2006 until 2022. She remains on the board as a non exec shareholder. She has 35 years experience in topoisomerase research along with an extensive background in the commercialisation of topoisomerase related products and drug screening.
Chairman of the Board, Non-Executive Director and Founder
Tony Maxwell is a biochemist (BSc UCL, PhD Bristol) based at the John Innes Centre in Norwich. His research work centres around DNA topoisomerases, enzymes that catalyse changes in DNA topology in all organisms. Topoisomerases have become key targets for antibiotics, anti-cancer drugs and potentially herbicides, and he is particularly expert on DNA gyrase, which is a well-validated target for antibiotics. His work involves determining the action of existing compounds and the development of novel compounds that target these enzymes. Along with Nick Burton and Alison Howells, he co-founded Inspiralis in 2006 and Chairs the Board and is Scientific consultant.
Business owner and entrepreneur who works with investors, startups and high potential companies across a range of business sectors.
Simon Saxby is an experienced company director and advisor. Until recently he was the Chief Executive Officer of Leaf Expression Systems Ltd and he is an advisor to the Board of CamCon Medical Ltd. His career in life sciences spans 40 years, with roles ranging from research scientist to chief executive officer of both private and public companies. He has been a founder and held senior management and director positions in biotech companies since 1987. He has led the design, build and operation of GMP manufacturing facilities in the UK, United States and Malaysia. He has also served as Visiting Lecturer in Industrial Biotechnology at the Vienna Medical and Technical University; Advisor at The Boston University School of Management, USA; and he is a visiting lecturer for the Cambridge University Masters in Biotechnology Enterprise (MBE) programme and a student mentor for Swansea University.